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Myocardial ﬂow reserve measurement is the gold standard for
isk stratiﬁcation in patients with suspected coronary artery dis-
ase [1]. Vasodilator pharmacological stress myocardial perfusion
maging is based on the heterogeneity of radioisotope uptake in the
yocardium being supplied by signiﬁcantly diseased versus non-
iseased coronary artery. Indications for pharmacological stress
est are listed in Table 1. Pharmacologic stress perfusion imaging is
n excellent adjunctive method for identifying high- and low-risk
atients from an intermediate-clinical risk pool [2,3].
Regadenoson, a selective adenosine A2A receptor agonist, is a
ovel pharmacologic stress agent under clinical development for
yocardial perfusion imaging [4]. Regadenoson was approved by
he US Food and Drug Administration (FDA) in 2008 in myocar-
ial perfusion studies. In Japan, dipyridamole and adenosine
riphosphate as well as adenosine had been used. The action of
ipyridamole is mediated by increasing endogenous adenosine at
able 1
ndications for pharmacological myocardial perfusion imaging.
Inability to exercise
- Physical limitations (elderly people, etc.)
- Recent operation
- Peripheral artery disease
Limited exercise capacity
-Medication such as beta-blocker
- Poor motivation for exercise
- Limited physical conditions
Contraindications to exercise
-Aortic aneurysm
-Acute coronary syndrome
- Severe aortic stenosis
False positive results may occur
- Left bundle branch block
-Ventricular pacing
-Wolff–Parkinson–White syndrome
DOI of original article: http://dx.doi.org/10.1016/j.jccase.2014.03.007.
ttp://dx.doi.org/10.1016/j.jccase.2014.03.004
878-5409/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. Open accessthe receptor site [5,6]. In 2006, adenosine was approved by the
Ministry of Health, Labour and Welfare in Japan for the use of
stress perfusion imaging. It enters the extracellular space by a
carrier-mediated mechanism after the injection of adenosine. It
also enters the intracellular space of endothelial, smooth muscle
by facilitated transport. Several types of adenosine receptors are
known. The adenosine A2 receptor is located on vascular cells,
which are divided into A2A and A2B. Coronary vasodilation is medi-
ated by the adenosine A2A receptor. The A2B and A3 receptors are
responsible for bronchospasm. The half-life of adenosine is short,
less than 2 s and adenosine has a rapid onset of action. Adenosine
can increase coronary blood ﬂow by 2.5-fold or greater. Therefore
adenosine is used for thenoninvasive evaluationofmyocardial ﬂow
reserve in the clinical setting. The most common reported side
effects of adenosine are ﬂushing, shortness of breath, and chest
pain, which usually disappear after the cessation of the infusion
[7]. First- and second-degree of atrioventricular (AV) blocks occur
in less than 10% of patients, and advanced AV block occurs in less
than 1% of patients [8]. The most severe side effect, that is, bron-
chospasm can be treated rapidly with 50–100mg of intravenous
theophylline, which competitively blocks the adenosine receptor.
Like adenosine, regadenoson causes coronary vasodilation
through its action on the adenosine A2A receptor subtype [9]. A2A
receptor stimulation seems to be a desired way to cause signif-
icantly higher myocardial blood ﬂow with more sustained hyper-
emia compared to adenosine. Regadenoson can be administered by
a single bolus injection of 0.4mg through peripheral vein without
weight-adjustment. There is no need to adjust the dose in patients
with renal failure as no adverse effects in patients with serum cre-
atinine clearance of <30ml/min have been observed. The effect of
regadenoson on coronary circulation (rapid increase to more than
2.5-fold over baseline) is sustained for approximately 2.3min and
decreases to less than twice the baseline level within 10min.
In the current issue of this journal, Junpaparp et al. [10] report
on a rare complication of regadenoson in a 63-year-old male
patient with ischemic stroke. After 5min of the stress test, a
patient developed generalized tonic–clonic seizure that lasted for
2min. It was concluded that seizurewas provoked by regadenoson.
Page et al. [11] reported three cases of seizures associated with
regadenoson. Recent clinical studies to examine the safety of
regadenoson have been reported. The drug could be used safely in
patients with chronic kidney disease [12]. Similarly, regadenoson
could be given with end-stage liver disease patients waiting
for liver transplantation [13]. Studies on patients with chronic
 under CC BY-NC-ND license.
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bstructive lung disease or asthma have reached the consensus
hat regadenoson can be used in patients with mild or moderate
eactive airway disease [14]. However, regadenoson should be
sed with caution in chronic obstructive lung disease patients
ith a 24-h/day home oxygen requirement, prior intubation for
espiratory failure, or recent exacerbation. ADVANCE MPI trials
howed that regadenoson achieved non-inferiority to adenosine
or pharmacologic stress test [15]. The agreement rates between
he initial adenosine procedure and the second randomized proce-
ure with either adenosine or regadenoson were almost identical.
ince regadenoson has the potential for improving stress tolera-
ility and a reduction in the number of serious adverse events, it
ppears to have appealing features for clinical use in Japan.
The safety of the drug is not completely assured for Japanese,
nder the circumstances that regadenoson is not yet approved
n Japan. Care should be taken in performing regadenoson stress
specially in patients with ischemic stroke or known seizure dis-
rder, considering that the true incidence of seizures induced by
egadenoson in these subjects is not known. Furthermore there is
o good reason to suspect that regadenoson would be superior to
denosine in themanagement of patientswith coronary artery dis-
ase. It would need further investigations in a larger clinical trial to
rasp the nature of this medicine.
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